Delayed
OTC Markets
|
5-day change
|
1st Jan Change
|
- USD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,154
|
193.1
|
65.46
|
145.1
|
266.6
|
-
|
-
|
Enterprise Value (EV)
1 |
838.6
|
-16.69
|
-57.35
|
145.1
|
266.6
|
266.6
|
266.6
|
P/E ratio
|
-15.6
x
|
-1.54
x
|
-0.71
x
|
-1.49
x
|
-3.33
x
|
-2.93
x
|
-2.76
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
68.5
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
68.5
x
|
EV / EBITDA
|
-16,595,135
x
|
-1,524,466
x
|
-709,045
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-22.1
x
|
-1.88
x
|
-0.77
x
|
-
|
-3.65
x
|
-2.82
x
|
-2.12
x
|
FCF Yield
|
-4.53%
|
-53.3%
|
-130%
|
-
|
-27.4%
|
-35.4%
|
-47.1%
|
Price to Book
|
3.76
x
|
0.98
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,996
|
36,229
|
36,366
|
51,635
|
56,253
|
-
|
-
|
Reference price
2 |
32.05
|
5.330
|
1.800
|
2.810
|
4.890
|
4.890
|
4.890
|
Announcement Date
|
21-03-25
|
22-03-17
|
23-03-09
|
24-03-12
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.893
|
EBITDA
|
-29.28
|
-69.52
|
-126.7
|
-92.32
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.33
|
-69.57
|
-126.9
|
-92.83
|
-86.46
|
-85.73
|
-112.4
|
-138.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,548.81%
|
Earnings before Tax (EBT)
1 |
-35.26
|
-67.25
|
-125.6
|
-91.17
|
-82.44
|
-80.88
|
-104.1
|
-123.3
|
Net income
1 |
-35.26
|
-67.25
|
-125.6
|
-91.17
|
-82.44
|
-81.62
|
-109.9
|
-135.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,479.09%
|
EPS
2 |
-16.99
|
-2.050
|
-3.470
|
-2.520
|
-1.880
|
-1.468
|
-1.670
|
-1.772
|
Free Cash Flow
1 |
-24.7
|
-52.29
|
-102.9
|
-85.27
|
-
|
-73
|
-94.5
|
-125.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,223.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-24
|
21-03-25
|
22-03-17
|
23-03-09
|
24-03-12
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-25.96
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.08
|
-25.68
|
-23.17
|
-22.12
|
-21.85
|
-21.56
|
-20.03
|
-24.01
|
-20.86
|
-20.25
|
-21.4
|
-21.79
|
-22.25
|
-27.49
|
-29.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-25.87
|
-25.51
|
-22.93
|
-21.65
|
-21.08
|
-20.88
|
-19.15
|
-23.01
|
-19.41
|
-18.22
|
-20.38
|
-20.88
|
-21.4
|
-25.06
|
-27.05
|
Net income
1 |
-25.87
|
-25.51
|
-22.93
|
-21.65
|
-21.08
|
-20.88
|
-19.15
|
-23.01
|
-19.41
|
-18.22
|
-20.65
|
-21.06
|
-21.5
|
-28.37
|
-30.36
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7100
|
-0.7000
|
-0.6300
|
-0.6000
|
-0.5900
|
-0.5700
|
-0.5200
|
-0.4500
|
-0.3400
|
-0.3500
|
-0.3867
|
-0.3683
|
-0.3667
|
-0.4450
|
-0.4675
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-17
|
22-05-11
|
22-08-09
|
22-11-08
|
23-03-09
|
23-05-09
|
23-08-11
|
23-11-06
|
24-03-12
|
24-05-09
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
315
|
210
|
123
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-24.7
|
-52.3
|
-103
|
-85.3
|
-
|
-73
|
-94.5
|
-126
|
ROE (net income / shareholders' equity)
|
-
|
-51.6%
|
-49.9%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-33.6%
|
-27.6%
|
-43.5%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
105.1
|
244
|
288.7
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-2.260
|
8.530
|
5.410
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
-
|
2.71
|
0.19
|
-
|
-
|
-
|
0.97
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.99%
|
Announcement Date
|
20-03-24
|
21-03-25
|
22-03-17
|
23-03-09
|
24-03-12
|
-
|
-
|
-
|
Last Close Price
4.89
USD Average target price
12.6
USD Spread / Average Target +157.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.30% | 116B | | +12.15% | 106B | | -8.14% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -15.33% | 16.33B | | +5.80% | 14.14B | | +28.03% | 12.02B |
Bio Therapeutic Drugs
|